Indinavir plasma levels are associated with antiretroviral efficacy however few data is available regarding toxicity. We assessed the relationship between indinavir pharmacokinetic (PK) characteristics and severe nephrolithiasis as well as other severe or serious adverse reactions (SAR). Patients included in the ANRS CO8 APROCO-COPILOTE cohort and receiving indinavir 800 mg thrice daily as first line protease inhibitor, were eligible for this study. To be included in the analysis, their plasma sample at month 1 (M1) had to be available (n=282) to estimate, using population PK modelling, indinavir PK characteristics, i.e. maximum (C max ) and trough plasma (C res ) concentrations, area under the curve (AUC) and observed/predicted concentrations ratio (CR). A Cox model was used to estimate the independent effect of C max , C res , AUC and CR on the hazard of severe nephrolithiasis and SAR. At M1, median C max was 6 205 ng/mL, C res : 631 ng/mL, AUC: 24 242 ng.h/mL and CR: 0.6. After a median follow-up of 12 months, 11% of patients (30/282) had experienced at least one SAR among which 12 were nephrolithiasis.
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INTRODUCTION
One of the main drawbacks of Highly Active Antiretroviral Therapy (HAART) is toxicity, leading to treatment discontinuations and limitation of treatment options. Among baseline characteristics, high plasma HIV RNA, elevated aspartate animotransferase (AST), reduced creatinine clearance, positive hepatitis C-virus (HCV) antibodies or hepatitis B (HB) antigenemia, gender, age and HIV transmission group are considered as determinants of protease inhibitor (PI) related toxicity (1, 2) . Among other potential determinants, PI plasma levels have been less studied although the measurement of drug concentration, i.e.
therapeutic drug monitoring (TDM), has shown a large interest in many diseases (3) (4) (5) , to improve efficacy and minimize toxicity. Moreover, PIs are good candidates for TDM because of high inter-patient variability in plasma concentrations, binding to plasma proteins, P450 3A4 cytochrom metabolism, short half-life, drug-food and drug-drug interactions (6, 7) that may lead to inadequate PIs exposure among patients receiving the same dose.
Many studies in HIV-infected patients have previously focused on a relationship between concentration and effect, in terms of virological response (8) (9) (10) (11) , whereas toxicity was a secondary outcome. When adverse events have become a major problem in treated HIV-infected patients, data found in the literature show insufficient evidence to recommend a general therapeutic range, probably because only few databases have both appropriate pharmacokinetics and toxicity data available, like in the ANRS CO8 APROCO-COPILOTE cohort.
The aim of our analysis was to assess the relationship between indinavir individual PK characteristics, one month after initiating indinavir containing therapy, and severe nephrolithiasis or any severe or serious adverse reactions (SAR), occurring in the following year, among patients included in an observational cohort of patients starting HAART with a PI-containing regimen.
PATIENTS AND METHODS
APROCO-COPILOTE cohort is a prospective observational cohort study of 1281 At a random time between intake and plasma sampling, a single blood sample was collected at M1. Indinavir plasma concentration was measured using a validated highperformance liquid chromatography method (12, 13) . The lower limit of quantification was 4 5 ng/mL. The interday and intraday coefficients of variation of the assay were less than 11% and 8%.
A one-compartment model with first-order absorption and elimination was used to describe the PK population parameters of indinavir as shown by Brendel et al (14) and used by Duval et al (11) . A population analysis (15) was performed to estimate both the mean and the inter-individual variability of the PK parameters included in this model, i.e. the clearance (CL) and the volume of distribution (V), the absorption rate constant (ka) being fixed to 0.49h -1 . From this population analysis, the individual parameters of the 282 patients were derived using Bayesian estimation (16) . The population analysis and the Bayesian estimation was performed using the FOCE method of NONMEM version 5 (UCSF, San
Fransisco, CA). Maximum (C max ) and trough (C res ) plasma concentrations were then calculated according to a classical steady-state formulae for repeated oral dose: At steady state, area under the plasma curve up to 8h after intake (AUC 0-8h ), was estimated by the Dose/CL ratio. The observed/predicted concentrations ratio (CR) was estimated by the ratio between the observed concentration and the predicted concentration at the same time using the mean population parameters estimated during the population analysis (10 indinavir occurring in the first year after initiating indinavir containing therapy, were taken into account because they are the most frequent and specific SAR related to indinavir use (18) (19) (20) (21) (22) (23) . Then, all SAR (including nephrolithiasis) and SAR excluding nephrolithiasis were studied in two secondary analyses. In all analyses, follow-up data were censored one month after first indinavir discontinuation or dose adjustment.
A Cox proportional hazards regression model was used to estimate the independent effect of the individual indinavir PK characteristics (C res , C max , AUC, CR) on the risk of first nephrolithiasis or SAR occurrence (depending on the analysis performed), and adjusted for potential other risk factors : age, gender (24, 25) , body weight (26) or body mass index (BMI) (18) or body surface area (BSA) as estimated by the Gehan and George formula (27) , alanine aminotransferase (ALT) and AST (28), HCV antibodies and HBs antigenemia serologic status (25) , creatinine clearance as estimated by the Cockcroft-Gault formula (29) , plasma HIV RNA, CD4+ T-lymphocyte count and adherence to indinavir, all assessed at M1. Assessment of adherence was made by a self-administrated questionnaire. 6 A patient was considered as fully adherent at the M1 visit if he/she declared that he/she had totally complied with his/her indinavir prescription during the 7 days before M1.
Quantitative variables with clinically relevant thresholds were analysed as categorical variables, i.e. CD4+ cell count categorised as ≤200, 200 to 500 and >500/mm 3 Moreover, as the model assumed that censored follow-up was not informative, i.e.
not related to toxicity, a robustness analysis was performed to check this hypothesis. For this purpose, toxicity was defined, depending on the analysis performed, as nephrolithiasis only or overall SAR, indinavir discontinuations more than 30 consecutive days for any adverse event or for nephrolithiasis only and dose adjustments.
RESULTS
Our analysis included mainly men (78%) in their forties (Table I) The median follow-up was 12 months. Thirty SAR occurred in the first year after initiating indinavir containing therapy. Twelve cases were nephrolithiasis (incidence density: 5% patient-years) whereas the 18 others were mainly hepatic cytolysis (n=6), hyperglycemia/diabetes mellitus (n=3) and death (one unexplained respiratory distress and one pancreatitis with lactic acidosis). The median time until the occurrence of the first nephrolithiasis was 5.5 months (IQR: 3.3-7.7 months).
The rate of SAR did not differ between patients with (n=282) and without indinavir sampling results (n=51) (p=0.81), neither their characteristics assessed at M1.
The mean and the inter-individual variability of the PK parameters included in the model, i.e. the clearance (CL) and the volume of distribution (V), according to the population analysis were respectively for CL : 32.1 L/h (standard error (SE): 5.7%) and 34% (SE: 52.4%); for V: 58.5 L (SE: 13.5%) and 227% (SE: 31%). 8 Nine of the 12 patients with nephrolithiasis were fully adherent (data missing for the 3 others) as compared to 214 of 270 patients without nephrolithiasis. In the univariate analysis, only estimated C res , C max , AUC and CR as well as plasma HIV RNA and age remained associated with a higher rate of nephrolithiasis, according to the best cut-off when categorised (Table II) . Nephrolithiasis occurred in 9 of the 88 patients having a C res above 1000 ng/mL at M1 and the probability of developing a first nephrolithiasis at month 12 (M12) was 14% when C res was above 1000 ng/mL at M1 versus 2% when C res was under 1000 ng/mL (Figure 2 ). In the multivariate analysis (Table II) , a C res plasma concentration above 1000 ng/mL at M1 remained the only independent determinant of a higher rate of nephrolithiasis (HR = 6.7; 95% confidence interval (CI) = 1.8-25.2; p<10 -2 ). The approach of minimum p-value associated to a cross validation confirmed the cut-off of C res of 1000 ng/mL and an association between a C res above 1000 ng/mL with a higher rate of nephrolithiasis (HR=4.1; 95% CI=1.3-12.8; p=0.02).
In the robustness analysis censoring indinavir discontinuations for nephrolithiasis and dose adjustments: a C res above 1000 ng/mL still remained independently associated with a higher rate of nephrolithiasis: HR=3.9 (95% CI=1.5-10.0; p=0.005), indicating that the impact of informative censoring was not large enough to modify the initial conclusions.
The median time until the occurrence of the first SAR was 4.5 months (IQR: 2.7-7.5 months). The probability of developing a first SAR at M12 was 21.7% when C res was above 1000 ng/mL at M1 versus 8.2 % when C res was under 1000 ng/mL. When any SAR were analysed, in a multivariate model, the following variables assessed at M1 were independently associated with a higher hazard of SAR: C res above 1000 ng/mL (HR=3.3; 95% CI=1.1-10.1; p<0.05), plasma HIV RNA (HR=0.2 for each lower 1 log 10 copies/mL; 95% CI=0.06-0.8; p<0.05) and estimated creatinine clearance under 70 mL/min (HR=2.7; 95% CI=1.0-7.3; p=0.05). In the robustness analysis, a C res above 1000 ng/mL was not associated with a higher rate of SAR: HR=1.7 (95% CI=0.8-3.5; p=0.13).
Unlike the two primary analyses, no significative association with C res (p=0.37) or other indinavir PK characteristics was shown, when the analysis considered as outcomes only the 18 SAR that were not nephrolithiasis.
DISCUSSION
In this population of initially PI-naïve patients, a C res of indinavir above 1000 ng/mL, assessed at the steady state of HAART, was associated with a sevenfold higher rate of nephrolithiasis in the following year. This result potentially justifies Therapeutic Drug
Monitoring during indinavir containing therapy.
Whereas the APROCO-COPILOTE cohort has included 513 unselected HIVinfected patients starting indinavir containing therapy, the present analysis was restricted to a sub-group of 282 patients. Although we acknowledge a potential lack of power, a selection bias is unlikely as the rate of SAR was similar in those patients with available plasma sampling and in those without. Therefore, we believe that indinavir C res at the proposed threshold is strongly associated with nephrolithiasis. Non compliance with water intake or hot environmental temperature are known to be associated with higher incidence of nephrolithiasis (21, 28, 32) , but were not available in our database. For instance, in a hot climate, excessive sweating leading to low urinary volume, may itself predispose to nephrolithiasis, because of a phenomenon of dehydration. In our study, as 7 on the 12 nephrolithiasis occurred between May and September, we believed that hot weather might have contributed to the occurrence of nephrolithiasis in patients having basal high indinavir plasma level. Even if food intake was not recorded in our database, we believe that a major bias due to food intake is unlikely. In the cohort, the current practice for the patients was to be on fasting conditions when they were sampled in the morning. If they already had their breakfast, we can assume that it was most often a continental breakfast, unlikely to be rich in fat. However, we did not record the specific information on fasting conditions in these patients and cannot take this into account in the analysis precisely. Finally, to our knowledge, indinavir pharmacokinetic characteristics are not so much affected by food intake, conversely to a drug such as nelfinavir. Moreover, drugs that might interact with indinavir (i.e. ketoconazole, rifabutine, rifampicine) have been rarely prescribed in this study.
Only few previous studies have shown a relationship between higher plasma PI concentration and higher toxicity (20, (33) (34) (35) (100/800mg) twice daily, higher indinavir C res was associated with higher rate of any toxicity. After initiation of ritonavir/indinavir regimen and sometimes after dose adjustment, indinavir C res was assessed and compared between patients with and without occurrence of toxicity. Toxicity including nephrolithiasis occurred more frequently when C res was above 500 ng/mL. Contrary to the present study, no specific approach was used to validate this cut-off. Even if the cut-off value of 1000 ng/mL, reported in our study, seems high compared with the range of 150 ng/mL to 500 ng/mL reported by others (6, 7, 23, 33) , it may be explained by the modelling estimate of C res , precisely 8 hours after last intake.
However, it is rarely reached in clinical practice since treatment is given the preceding evening. Knowing the short indinavir half-life, plasma concentrations are twice lower every 90 minutes, leading to lower observed C res if one does take into account the time interval between last intake and sampling.
Although we acknowledge that indinavir is rarely used without ritonavir in the actual clinical practice, we believe that the design of the present study is valuable for other PI-containing therapies. As already underlined, the prospective observational cohort design of the present study, the population PK modelling and the cut-off determination by a formal strategy are valuable tools that can be recommended for further toxicity-plasma levels 12 relationship studies. It also could give complementary data on potential indinavir cut-off in patients using ritonavir-boosted indinavir combination, since it has been well established that ritonavir considerably boosted indinavir C res (38) . This seems all the more important to early monitor indinavir concentration to avoid indinavir C res above 1000 ng/mL as Brendel et al have recently shown in patients receiving ritonavir/indinavir (100/800mg) twice daily that, median indinavir trough concentrations ranged from 700 ng/mL to 1250 ng/mL (14) . that the most discriminating cut-off associated with virologic response was 194 ng/mL (11) , in a population of fully adherent patients receiving indinavir 800 mg tid at M4 from the APROCO/COPILOTE cohort and using a similar PK modelling, our results demonstrate that C res plasma concentration of indinavir above 1000 ng/mL is associated with a higher risk of nephrolithiasis occurrence. We may so suggest that the optimal therapeutic range of indinavir C res could be 200 ng/mL to 1000 ng/mL. On the basis of these data, prospective and early assessments of indinavir C res through therapeutic drug monitoring might be justified to allow dosage adjustment, while maintaining indinavir levels above efficacy threshold. 
